Hikma
HIK
Performance
About Hikma
Hikma is a global pharmaceutical company that develops, manufactures, and distributes high-quality generic medicines and injectables across North America, the Middle East and North Africa (MENA), and Europe. The company focuses on making affordable medicines accessible to patients, while expanding its product portfolio through R&D and contracted manufacturing capabilities. Hikma emphasizes responsible business practices and sustainability as part of its mission to improve health and wellbeing in communities worldwide.
Recent News
Justices Poised to Protect Generics Manufacturers From Liability for Decisions of Pharmacists About Prescribing Their Products
Amarin V. Hikma: Settling the Skinny Label Question
Pfizer Deals Extend Patent Life for a Top-Selling Rare Disease Drug
Hikma and Amarin's Generic Drug Case Heads to Supreme Court Arguments
Pharmaceutical Executive Daily: Supreme Court Unanimously Rules in Favor of Hikma Pharmaceuticals in Skinny Label Case
Hikma V. Amarin: The Amici Speak – Part II
The Fatal Conceit of Cheap Drugs
From AI to Smart Factories: How Pharma Is Preparing for 2026
U.S. Supreme Court Sides with Generic Drug Maker for Severe Hypertriglyceridemia Agent Icosapent Ethyl
Industry Outlook 2026: Navigating AI, Sustainability, and Operational Resilience
How a Supreme Court Fight over Fish Oil Could Raise Your Prescription Drug Costs
Lawmakers Warn Against Weakening IP for Medicines in House Hearing
AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings
Recent Deals
No recent deals for this company.